Skip to content

Biohaven BHVN Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
Roivant Sciences logo
Roivant SciencesROIV
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ADMA Biologics logo
ADMA BiologicsADMA
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's common stock, shares issued (in shares)?
Biohaven (BHVN) reported common stock, shares issued (in shares) of $150.51M in Q1 2026.
How has Biohaven's common stock, shares issued (in shares) changed year-over-year?
Biohaven's common stock, shares issued (in shares) increased by 47.4% year-over-year, from $102.1M to $150.51M.
What is the long-term trend for Biohaven's common stock, shares issued (in shares)?
Over 3 years (2022 to 2025), Biohaven's common stock, shares issued (in shares) has grown at a 24.9% compound annual growth rate (CAGR), from $68.19M to $132.78M.